Belgium · Delayed Price · Currency is EUR UCB SA Earnings Call Transcripts
Fiscal Year 2026
-
BIMZELX continues to gain global traction, especially in HS, with robust long-term data supporting its efficacy and safety. Early and first-line use leads to superior outcomes, and quality of life improvements are significant. Access is expanding, and while new oral therapies are emerging, injectables remain preferred due to efficacy.
-
A decade of growth is underway, fueled by strong execution, strategic acquisitions, and innovation in immunology and neurology. BIMZELX leads with unique efficacy and expanding access, while the pipeline advances in atopic dermatitis, severe epilepsy, and T-cell engager therapies.
-
The session highlighted robust H1 growth, upgraded guidance, and a focus on long-term innovation. BIMZELX remains the primary growth driver, with expanding indications and strong access strategies. Early-stage pipeline assets and targeted commercial execution underpin confidence in sustained growth and margin expansion.
-
First-half 2026 saw net sales rise 23% to EUR 4.1 billion, driven by five growth products now over half of revenue. Upgraded guidance reflects strong BIMZELX momentum, new peak sales target above EUR 7 billion, and robust pipeline expansion through acquisitions and clinical advances.
-
BE BOLD demonstrated bimekizumab's statistically significant superiority over risankizumab in joint outcomes for psoriatic arthritis, with sustained efficacy and a safety profile consistent with prior studies. The results are expected to influence clinical guidelines, prescribing practices, and payer dynamics, supporting bimekizumab's positioning as a first-line therapy.
-
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
Fiscal Year 2025
-
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
-
First-half 2025 saw 26% net sales growth, led by BIMZELX and strong pipeline progress. Upgraded full-year guidance reflects confidence in continued momentum, despite pricing and currency headwinds. BIMZELX's global expansion and new indications underpin robust financial and operational performance.
-
The growth outlook is supported by five launch-phase products, improved U.S. BIMZELX access for 2025 and positive feedback across markets. Pipeline priorities include further study of bepranemab subgroups and a second lupus Phase III now underway.
Fiscal Year 2024
-
2024 saw a robust financial turnaround with 17% revenue growth, strong performance from key assets like BIMZELX and FINTEPLA, and a positive outlook for 2025 with double-digit revenue and margin expansion expected. Strategic divestments and pipeline progress further strengthened the growth platform.
-
Net sales grew 11% year-over-year, driven by strong launches of five key assets and robust global uptake, especially for BIMZELX and RYSTIGGO. EBITDA margin was 23% amid increased investment, with 2024 revenue expected at the top end of guidance and ambitious 2025 targets reaffirmed.